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Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy 
subjects
C. van Gulpen, O. Kelder, H. Mattie, J. YV. M . van der Meer and J. van’t Wout
t
Leiden University Hospital, Department o f  Infectious Diseases, Rijnsburgerweg 10,
2333 A A Leiden, The Netherlands
The role of gastric acidity in the absorption of the new antifungal drug vibunazole 
was studied in six healthy volunteers. Vibunazole was administered orally as 400 mg 
tablets to fasting subjects under three conditions: after 400 mg cimetidine orally, 
after 30 ml diluted hydrochloric acid orally, and alone. Plasma concentrations of 
vibunazole were determined with HPLC. The plasma concentration profile of 
vibunazole could be described adequately by a one-compartmental open model with 
first-order absorption. Kinetic parameters after oral administration did not differ 
between the three modes of administration. The mean peak time was 1 h 29 min (after 
lag-time). The mean peak concentration was 2-76 mg/1. The mean elimination half-life 
of vibunazole was 2 h 22 min. The mean absorption lag-time was 30 min, with 
considerable variation.
Introduction
Recently, a new class o f  oral an t i-m ycotic  d rugs  has been developed. V ibunazole  is a 
triazole c o m p o u n d  with a m o d e  o f  ac t ion  similar to th a t  o f  ketoconazole ,  an  imidazole- 
derivative. Its an t im ycotic  spec trum  differs f rom th a t  o f  ke toconazo le  in th a t  the 
Aspergillus species are sensitive to v ibunazole  (M eun ie r -C arpen t ie r  et al., 1983). Like 
ketoconazole ,  v ibunazole  is abso rbed  after  oral adm in is t ra t ion  (van der  M eer  et al., 
1980). Because the ab so rp t io n  o f  ke toconazo le  is greatly im paired  at  low gastric acidity 
(van der  M eer  et al., 1980) the present s tudy was u n d e r tak en  to establish the influence o f  
gastric acidity on  the ab so rp t io n  o f  v ibunazole  in hea lthy  volunteers.
Materials and methods
Experim ental design
Subjects were six healthy  volunteers  (5 female, 1 male), all o f  w h o m  had  no rm a l  renal 
‘ an d  hepatic  funct ion  and  used no o the r  medication .  T he  volunteers,  w ho were in form ed 
in detail a b o u t  the pu rpose  an d  design o f  the experiment,  were divided into  two groups  
o f  three subjects each. Each  subject received a tablet  con ta in ing  400 mg v ibunazole  to be 
taken  orally on three occasions at intervals o f  at  least two weeks and  u n d e r  three differ­
ent cond i t ions  accord ing  to a Latin  square: fasting w i th o u t  any add i t iona l  medicat ion;  
fasting two h ou rs  af ter  oral  adm in is t ra t io n  o f  400 mg cimetidine; fasting 1 h after  oral 
adm in is t ra t ion  o f  30 ml 0T N  hydroch lor ic  acid.
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Determination o f  plasma concentrations
Plasma concen tra t ions  o f  v ibunazole  were m easured  by reversed-phase H P L C ,  as a 
modification o f  the m e thods  earlier described (Alton, 1980; A ndrew s et al., 1981). The  
H P L C  system consisted o f  the following com ponents :  a solvent-delivery p u m p  L C 4 1 4  
(K ipp  & Zonen ,  Delft, The  Netherlands) ,  a model U 6 K  injector (W aters  Ass. M ilford ,  
Mass.,  USA), a variable wavelength U V -de tec to r  (K R A T O S -773 ,  K ipp  & Z onen ,  
Delft, The N ether lands)  and a flat-bed recorder  BD-40 (K ipp  & Zonen ,  Delft ,  The  
Netherlands) .  The  co lum n (length 10 cm, ID  3-0 m m ) was packed  with MOS-hypersil  
(particle-size 5 jim).
The following condi t ions  were employed: U V -de tec to r  setting at 231 nm, a flow-rate 
o f  l -5 m l /m in ,  and  a char t  speed o f  2 m m /m in .  S ta t ionary  phase: M OS-hypersi l  5 jim. 
Mobile  phase: 0 05 m ( N a H 2P 0 4/ N a 0 H )  buffer (pH 7-5)— acetonitr i le  (64:36 v/v). The  
retention time o f  v ibunazole in this system is 5-5 min.
Stock solutions were prepared  by dissolving 10 mg o f  v ibunazole  in 50 ml o f  m ethanol .  
A p p ro p r ia te  am o u n ts  o f  this s tanda rd  solution were added  to b lank  p lasm a to yield 
concen tra t ions  o f  0-2, 0-5, 1-0, 2-0, 5-0 and  10-0 mg/1 o f  vibunazole.
An a l iquot  (250 jil) o f  p lasm a was transferred  to a 10 ml test tube, alkanilized with 
50 |il M N a O H  solution and  then extracted with 3 ml o f  n-hexane by vortex mixing for 
10 sec. Separa t ion  o f  the layers was facilitated by centrifuging for 1 min at lOOOg. 
Tw o ml o f  the organic  phase was transferred  to a 20 ml glass vial. The  p lasm a was re­
extracted by add ing  2 ml o f  n-hexane to the test tube and  repeating the procedure .  The 
collected organic  phases were evapora ted  in a gentle n i trogen stream. T he  residue was 
dissolved in 250 jil o f  a mixture  o f  acetonitrile  and  w ater  (1/1). All concen tra t ions  
o f  v ibunazole  in the u n k n o w n  plasma samples were de term ined  on the day  o f  the 
experiment.
The  concen tra t ions  o f  v ibunazole were calculated from the peak  heights in the 
u nk n o w n  plasm a samples and  the spiked samples as p repared  for the ca l ibra t ion  curves. 
It appeared  tha t  the use o f  an internal s tan d a rd  was not  necessary because o f  the great 
reproducibil i ty  o f  the assay procedure  as described above. The  re la t ionship  between the 
peak heights o f  the aqueous  s tanda rds  and  the concen tra t ions  o f  v ibunazole  as well 
as tha t  between s tanda rds  and  the spiked p lasm a extracts  appea red  to be linear, with 
corre la t ion  coefficients am o u n t in g  to 0-999 and  0*998 respectively, in the concen tra t ion  
range from 0-2 to 10-0 mg/1. The  recovery was calculated as 83%  ( s . d .  0-8%).
Pharmacokinetic analysis
A p p aren t  e l imination rate cons tan ts  were calculated from the terminal slope (from 3 h 
onw ards)  o f  the log p lasm a concen tra t ion  time curve. T he  area  under  the p lasm a 
concen tra t ion  time curve (A U C ) was established accord ing  to the t rapezoid  m ethod ,  
ex trapo la ted  to infinity.
A bsorp t ion  was calculated according  to W agner  & Nelson (1963) as
A
— =  C, +  k c* A U C „
V ( 1)
in which A t is the a m o u n t  abso rbed  at time t, V is the a p p a re n t  volume o f  d is tr ibu t ion ,  C, 
the concen tra t ion  at time t, k e the el imination rate cons tan t ,  and  A U C ( the area under  
the p lasma concen tra t ion  time curve from 0 to time t.
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Figure I. An example o f  the plasma concentration time curves o f  vibunazole. Tablets of  400 mg were 
administered without an adjuvant  ( O )  o r  together with 30m l 0-1 /V hydrochloric acid ( □ )  or 4 00 m g  
cimetidine ( • ) .
Table I. Pharmacokinetic parameters of vibunazole after oral administration
(mean +  s.D.)
alone
Conditions of administration
with cimetidine with hydrochloric acid
K e i h - ” 0-277 (0-07) 0 312 (0*1) 0-29 (0-07)
A ' a i h - 1) 1 25 (0-27) 0-15 (0-59) 0-51 (0-6)
AUC0_X (mg/l.h.) 14-2 (3-6) 14-2(2-1) 15-2(3-3)
Lag-time (min.) 26-1 (14-7) 30-1 (12-3) 32-0(13-3)
The calculated values o f  A J V  were sub trac ted  from the ap p a ren t  maximal value o f  
A J V  and  plo tted  logarithmically against  time. The abso rp t io n  rate cons tan t  k a and  the 
abso rp t ion  lag-time T  were calculated accord ing  to the following equation;
A. A max
v v (1 ).
The time o f  m axim al concen tra t ion  was calculated as
t max
In k — Ind  I
K  -  K
and  the maximal concen tra t ion  as
C max
k ,  x k  - k ( t  - T )  
A U C x - -------- e  eWmax M ' m a x - T )
(2)
(3)
(4)
Results
A representative example o f  concen tra t ion- t im e  curves after  oral adm in is t ra t ion  o f  
400 mg vibunazole  is given in F igure  1. Calcula ted  pharm acok ine t ic  param eters  for all 
volunteers  are given in Table  I. Using the m ean  values o f  the pharm acok ine t ic
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Figure 2. Plasma concentrations o f  vibunazole after 400 mg orally. The curves were constructed with the
mean values o f  the pharmacokinetic  parameters  in six volunteers. W ithout  an a d ju v e n t ------ , with 30 ml 0* 1 /V
hydrochloric a c id ---------, and 400 mg cimeditine
param eters  for the three condit ions ,  average p lasm a concen tra t ions  curves were 
construc ted  (F igure  2).
Analysis o f  variance showed tha t  the a p p a re n t  el imination rate  cons tan ts  did no t  
differ significantly between the different m odes  o f  adm in is t ra t ion  (F2 10 =  0-30; 
P > 0  05). The m ean  el imination rate cons tan t  co rresponds  with an  a p p a re n t  half-life o f
2 h 22 min.
The A U C ,  ex trapo la ted  to infinity, was very similar for the three m odes  o f  adm in is ­
tra t ion,  indicating tha t  the tota l  a m o u n t  abso rbed  did no t  differ (F2 10 =  0-33; 
P > 0  05).
The abso rp t ion  rate cons tan ts  for the three condi t ions  did no t  differ significantly
2, io =  0 33; P > 0 •05); the m ean  value co rresponds  with an  ab so rp t io n  half-life o f  
32 min.
There  was a wide varia t ion  in lag-times, bu t  again no appreciab le  difference between 
the modes o f  adm in is t ra t ion  (F 2 10 =  0*53; P >  0 05); the m ean  lag-time was 30 min.
The m ean  maximal concen tra t ion  and  time o f  m axim al concen tra t ions  calculated 
by subst i tu t ing  m ean  values o f  the pharm acok ine t ic  p a ram ete rs  in equa t ion  (3) and
equa t ion  (4) were 2-76 mg/1 and  1 h 29 min (after lag-time), respectively.
Discussion
O u r  results show that,  in con tras t  with ke toconazole  (van der  M eer  et al., 1980), the 
abso rp t ion  o f  v ibunazole  af ter  oral adm in is t ra t ion  is no t  changed  either by enhanc ing  
gastric acidity by oral adm in is t ra t ion  o f  hydrochlor ic  acid or by inhibit ing secretion o f  
gastric juice by oral adm in is t ra t ion  o f  cimetidine (D ouglas ,  1980), co m p ared  with the 
abso rp t ion  o f  v ibunazole  taken with water.
Since, the ap p a ren t  e l imination  rate is very similar for the three m odes  o f  adm in is ­
tra t ion,  the calculated abso rp t io n  rate cons tan ts  as well as the ex trapo la ted  areas  under
C. van Gulpen et al.
Vibunazole pharmacokinetics 79
the curve are reliable parameters of absorption under the three conditions. The absorp­
tion is remarkably uniform with little variation; this suggests that absorption is almost 
total. The lag-time showed a relatively large variation probably due more to the 
experimental conditions (fasting) than to variation in dissolution time.
Therefore, unlike ketoconazole, the orally administered antifungal drug vibunazole is 
very reliably absorbed and this process is not influenced by gastric acidity. This could be 
an advantage in the oral treatment of fungal infections.
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